Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2001-03-21
2003-12-23
Fredman, Jeffrey (Department: 1655)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091100, C435S285200, C435S287200, C536S022100, C536S024320
Reexamination Certificate
active
06667155
ABSTRACT:
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is based upon and claims the benefit of priority from the prior Japanese Patent Applications No. 2000-080955, filed Mar. 22, 2000; and No. 2001-062372, filed Mar. 6, 2001, the entire contents of both of which are incorporated herein by reference.
BACKGROUND OF THE INVENTION
The present invention relates to a carrier for gene detection, a method for detecting validity of interferon therapy on individuals, a gene detecting apparatus for detecting validity of interferon therapy on individuals, and a gene detection kit for detecting validity of interferon therapy.
In recent years, patients infected with hepatitis C viruses (to be called HCV hereafter) have rapidly increased, leading to a great social problem.
Although interferon therapy has been revealed to have a certain effect on hepatitis C as well as on other viral illnesses, interferon therapy is not effective to all the infected patients, and there are not a few patients who has no sensitivity to interferon and cannot benefit from interferon therapy. Continuation of interferon therapy to such patients who exhibit no sensitivity to interferon would not only cause side effects such as fever and anemia to the patients but also delay initiation of other expected therapies.
Therefore, there has been longed for a method of predicting whether interferon therapy is effective or not to an HCV-infected patient to be treated, but such prediction has not at all been possible.
BRIEF SUMMARY OF THE INVENTION
An object of the invention is to provide a method for predicting whether interferon therapy is effective to a patient, before the treatment is effected.
According to the first aspect of the present invention, there is provided a carrier for gene detection, which comprises:
a base body; and
a polynucleotide immobilized on the base body, the polynucleotide comprising a polynucleotide selected from the group consisting of:
(at) the polynucleotide of Sequence ID No. 1 in the sequence listing;
(bt) a modified polynucleotide derived from the polynucleotide (at) by including one or several deletions, substitutions or additions at any positions except for 455th position;
(ct) a polynucleotide containing the sequence which spans from 441st to 455th position of Sequence ID No. 1;
(dt) a polynucleotide containing the sequence which spans from 449the to 459th position of Sequence ID No. 1; and
(et) a complementary strand of the polynucleotide selected from the group consisting of (at), (bt), (ct) and (dt) mentioned above.
According to the second aspect of the present invention, there is provided a carrier for gene detection which comprises:
a base body; and
a polynucleotide immobilized on the base body, the polynucleotide comprising a polynucleotide selected from the group consisting of:
(ag) the polynucleotide of Sequence ID No. 2 in the sequence listing;
(bg) a modified polynucleotide derived from the polynucleotide (ag) by including one or several deletions, substitutions or additions at any positions except for 455th position;
(cg) a polynucleotide containing the sequence which spans from 441st to 455th position of Sequence ID No. 2;
(dg) a polynucleotide containing the sequence which spans from 449th to 459th position of Sequence ID No. 2; and
(eg) a complementary strand of the polynucleotide selected from the group consisting of (ag), (bg), (cg) and (dg) mentioned above.
According to the third aspect of the present invention, there is provided a carrier for gene detection which comprises:
a base body; and
a polynucleotide immobilized on the base body, the polynucleotide comprising a polynucleotide selected from the group consisting of:
(aa) the polynucleotide of Sequence ID No. 3 in the sequence listing;
(ba) a modified polynucleotide derived from the polynucleotide (aa) by including one or several deletions, substitutions or additions at any positions except for 455th position;
(ca) a polynucleotide containing the sequence which spans from 441st to 455th position of Sequence ID No. 3;
(da) a polynucleotide containing the sequence which spans from 449th to 459th position of Sequence ID No. 3; and
(ea) a complementary strand of the polynucleotide selected from the group consisting of (aa), (ba), (ca) and (da) mentioned above.
According to the fourth aspect of the present invention, there is provided a carrier for gene detection which comprises:
a base body; and
a polynucleotide immobilized on the base body, the polynucleotide comprising a polynucleotide selected from the group consisting of:
(ac) the polynucleotide of Sequence ID No. 4 in the sequence listing;
(bc) a modified polynucleotide derived from the polynucleotide (ac) by including one or several deletions, substitutions or additions at any positions except for 455th position;
(cc) a polynucleotide containing the sequence which spans from 441st to 455th position of Sequence ID No. 4;
(dc) a polynucleotide containing the sequence which spans from 449th to 459th position of Sequence ID No. 4; and
(ec) a complementary strand of the polynucleotide selected from the group consisting of (ac), (bc), (cc) and (dc) mentioned above.
According to the fifth aspect of the present invention, there is provided a DNA chip, which comprises:
a base body; and
a first and a second electrodes formed on the base body,
the first electrode comprising a conductive body and at least one polynucleotide immobilized on the conductive body, the polynucleotide being selected from the group consisting of (at) to (et) shown below;
(at) the polynucleotide of Sequence ID No. 1 in the sequence listing;
(bt) a modified polynucleotide derived from the polynucleotide (at) by including one or several deletions, substitutions or additions at any positions except for 455th position;
(ct) a polynucleotide containing the sequence which spans from 441st to 455th position of Sequence ID No. 1;
(dt) a polynucleotide containing the sequence which spans from 449the to 459th position of Sequence ID No. 1; and
(et) a complementary strand of the polynucleotide selected from the group consisting of (at), (bt), (ct) and (dt) mentioned above, the second electrode comprising a conductive body, and at least one polynucleotide immobilized on the conductive body, the polynucleotide being selected from the group consisting of (ag) to (eg), (aa) to (ea), and (ac) to (ec) shown below;
(ag) the polynucleotide of Sequence ID No. 2 in the sequence listing;
(bg) a modified polynucleotide derived from the polynucleotide (ag) by including one or several deletions, substitutions or additions at any positions except for 455th position;
(cg) a polynucleotide containing the sequence which spans from 441st to 455th position of Sequence ID No. 2;
(dg) a polynucleotide containing the sequence which spans from 449th to 459th position of Sequence ID No. 2;
(eg) a complementary strand of the polynucleotide selected from the group consisting of (ag), (bg), (cg) and (dg) mentioned above;
(aa) the polynucleotide of Sequence ID No. 3 in the sequence listing;
(ba) a modified polynucleotide derived from the polynucleotide (aa) by including one or several deletions, substitutions or additions at any positions except for 455th position;
(ca) a polynucleotide containing the sequence which spans from 441st to 455th position of Sequence ID No. 3;
(da) a polynucleotide containing the sequence which spans from 449th to 459th position of Sequence ID No. 3;
(ea) a complementary strand of the polynucleotide selected from the group consisting of (aa), (ba), (ca) and (da) mentioned above;
(ac) the polynucleotide of Sequence ID No. 4 in the sequence listing;
(bc) a modified polynucleotide derived from the polynucleotide (ac) by including one or several deletions, substitutions or additions at any positions except for 455th position;
(cc) a polynucleotide containing the sequence which spans from 441st to 455th position of Sequence ID No. 4;
(dc) a polynucleotide containing the sequence which spans from 449th to 459th position of Sequence ID No. 4; and
(ec) a complementary strand of the polynucleotide selected from the grou
Hashimoto Koji
Hijikata Minako
Mishiro Shunji
Oota Yasuhiko
Chakrabarti Arun K.
Fredman Jeffrey
Kabushiki Kaisha Toshiba
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
LandOfFree
Carrier for gene detection and its use for detecting... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Carrier for gene detection and its use for detecting..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Carrier for gene detection and its use for detecting... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3122126